CG Oncology, Inc

CG Oncology, Inc., based in Irvine, CA, is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing oncolytic immunotherapies aimed at treating bladder cancer while striving for a bladder-sparing approach. Their investigational drug, cretostimogene grenadenorepvec, has demonstrated clinical benefits in patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and is being evaluated in ongoing clinical trials.

Committed to improving the quality of life for urologic cancer patients, CG Oncology focuses on innovative treatments that can enhance patient dignity and overall well-being. Recent updates highlight promising data from their clinical trials, showcasing the efficacy and durability of their therapeutic approaches in managing bladder cancer.

Generated from the website